Frontier technology, unparalleled.
Product: Nexstim NBS
Nexstim Navigated Brain Stimulation (NBS) uses SmartFocus® transcranial magnetic stimulation to precisely localise and accurately modulate the surface of the brain associated with eloquent function. With spatial accuracy reported between 2-6mm, Nexstim data yields clinically meaningful information in neurosurgery, cerebrovascular surgery, epilepsy surgery and radiation therapy.
Then use EnTMS data during surgery to avoid neurologic injury.
Safely map eloquent motor and language regions prior to surgery
Indication of craniotomy size and surgical exposure
Functionally confirm involvement of eloquent motor and language regions
Neurologic risk stratification (i.e., lesion to tract distance, interhemispheric motor resting threshold).
Indication of and complimentary to brain mapping & monitoring
Indication of surgical approach (i.e., awake or asleep) in consideration of nTMS functional data.
Accuracy and integration of DTI fiber tractography
Close corroboration with direct cortical stimulation data (< 2-6mm)
"What makes this so special is the ability for it to define very small, precise cortical regions on the surface of the brain, and define individual components of function, which is something we never could do before"
Prof Mitch Berger
Neuroclast is a proud business and collaborative partner with Nexstim to introduce navigated transcranial navigation to the Australian and New Zealand markets.
EnTMS is currently being outsourced by Neuroclast in Melbourne, AUS.
Please inquire if you would like to refer a patient, or arrange a demonstration.
We have designed and instituted a multi-centre trial for EnTMS in supratentorial brain tumour surgery to explore the impact it can have on surgical planning, clinical outcomes, and direct cortical stimulation findings.
What is Navigated TMS?
Transcranial magnetic stimulation (TMS) introduced in 1985.
Initially developed as a research tool, integration with stereotactic neuro-imaging rendered it a prospective clinical tool.
Line navigation was insufficient for precise targeting of neural function.
Nexstim was the first, and only, medical device company to localise the coil's true electric field (E-field) relative to the brain.
Partnered with MRI neuro-imaging En-TMS is the most accurate and precise product in the world for presurgical mapping and therapeutic applications.
Nexstim's accuracy and clinical efficacy is supported by peer-reviewed medical research.
An electromagnetic field can be created that generates an electrical field at the surface of the scalp. There are various types of "coils" that can induce different stimulation effects on the human brain. Traditionally, TMS is stimulated with an approximate understanding of anatomic targets.
Stereotactic imaging uses a three-dimensional coordinate system for anatomical targeting, compared to other imaging modalities which are 2D. This makes targeting more effective, especially if you're trying to localise eloquent cortical regions that have important implications for treatment.
Line navigation refers to how the TMS system's coils align with the imaging relative to the scalp. Given that TMS coils are often bulky, it is difficult to partner stereotaxy with these coils.
This is critically important when making treatment-related decisions inferred from TMS data. Nexstim's SMART FOCUS technology is novel and patented, and contributes to the most accurate, precise and reproducible electrical field possible.
In the context of neurosurgery, accuracy of non-invasive mapping such as En-TMS is crucial. Nexstim's NBS and NBT systems use the SMART FOCUS technology to ensure that data is accurate and can be exported in DICOM format into all intraoperative navigation systems.
Over 100 peer-reviewed papers involving 4,000+ patients have been published throughout the U.S, EU and U.K as of 2020. Neuroclast is establishing formal research partnerships with tertiary and non-tertiary hospitals using the NBS and NBT systems.
Contact Neuroclast for an inspection or demonstration of the NBS or NBT system today.